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IntroductIon
Endocrine and metabolic paraneoplastic syndromes, occurring in 
5–10% of malignant tumours, result from ectopic production of 
hormones or hormone precursors in tumour cells. One of the most 
frequently produced hormones is adrenocorticotropin, which is 
responsible for increased cortisol secretion from adrenal cortex 
and occurrence of Cushing’s syndrome symptoms. Patients usually 
develop hypertension, diabetes mellitus, osteoporosis and alkalo-
sis with low plasma potassium level. Other possible symptoms in-
clude: characteristic distribution of fat tissue (central obesity and 
the so called «buffalo hump»), muscle weakness, stretch marks 
on the skin, acne, emotional lability, and – in women – disturbed 
menstrual cycle. The documented sources of ectopic ACTH, pro-
duced by nonpituitary cancers, include some small cell lung can-
cers, pancreatic islet cell tumours, thymomas, medullary hyroid 
cancers, bronchial carcinoid tumours, and hepatic carcinoid tu-
mours [1–4]. Production of adrenocorticotropin by glandular can-
cers [1–5], especially breast cancer, is sporadic (<1%) [6–8]. The 
study presents a case of a triple-negative invasive breast cancer with 
neurendocrine differentiation and ectopic production of ACTH.
case report
A 57-year-old woman with recently diagnosed diabetes mellitus 
type 2, grade 3 hypertension according to ESC (European Society 
of Cardiology), central obesity and no family history of cancer, was 
admitted for diagnostic tests of hypercorticism occurring with 
severe hypokalemia (1.6 mmol/L) and cardiac insufficiency. The 
patient also had muscle weakness and stretch marks on the skin. 
During hospitalisation, biochemical tests confirmed the working 
diagnosis, ACTH-dependent Cushing’s syndrome (cortisol level at 
6 a.m. 125,1 µg/mL [5–25 µg/dL]; cortisol level at 12 pm 73.70 µg/
dL [0–5 µg/dL]; 17–OHCS level in 24-hour urine collection 30.2 
mg/24h [2.2–7.0 mg/24 h]; ACTH level 280 pg/mL [6.0–56.0 pg/
mL]; Aldosterone level 33.70 pg/mL [7.5-60 pg/mL]). The bone 
density scan, magnetic resonance imaging of the head, comput-
ed tomography of the abdomen and chest, as well as scintigraphy 
were performed to differentiate the cause of Cushing’s syndrome 
between ectopic ACTH secretion, hormonally active adrenal tu-
mor and hormonally active pituitary tumor (Cushing’s disease). 
A bone density scan showed slightly lowered bone density. Imag-
ing examinations showed bilateral adrenal hyperplasia, no focal 
lesions in the pituitary gland, and a stage cT3N1M0 cancer lesion 
in the superior lateral quadrant of the right breast. A scintigraphy 
with 99m-Tc-labelled somatostatin analogue showed increased re-
ceptor expression in the described breast tumour (Fig. 1). In both 
mammogram and US examination, the tumour was well defined 
and it had polycyclic outline. A histopathological examination of 
a biopsy specimen revealed an infiltration of cancer with a triple-
negative receptor status (estrogen receptor – 0; progesterone re-
ceptor – 0; HER2 [human epidermal growth factor receptor 2] 
– 2+; FISH [fluorescent in situ hybridization] – negative; Ki67 > 
50%). An immunohistochemical test confirmed it was an epithelial 
tumour (positive reaction for the presence of cytokeratins AE1 and 
E3 and epithelial membrane antigen [EMA]). Following oncologi-
cal and surgical consultation, due to increased metabolic distur-
bances, the idea of induction chemotherapy was abandoned, and 
the patient was qualified for surgical treatment. At the preoperative 
stage the patient received steroidogenesis inhibitors (mitotane and 
metyrapone) and somatostatin analogue (octreotide), her diabe-
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from the presence of the tumour or metastasis, but from endo-
crine activity of the tumour. Ectopic production occurs the most 
frequently with respect to the following hormones: adrenocor-
ticotropin, human chorionic gonadotropin (HCG), antiduretic 
hormone (ADH), parathormone (PTH), growth hormone (GH), 
prolactin (PRL), gastrin, glucagon, renin and erythropoietin. These 
substances produced by tumour cells may cause metabolic, dystro-
phic and/or degenerative changes of various degrees of intensity.
In literature, neuroendocrine differentiation of primary breast 
cancer occurs in approximately 21% of cases [9]. It is estimated 
that in 16% of patients, especially after menopause, expression of 
ACTH can be found [6]. Contrary to bronchial carcinoid tumours 
and small cell lung cancers causing ectopic production of adre-
nocorticotropin, where a majority of patients have clinically overt 
hypercorticism [1–3], breast cancers with hormonal activity give 
Cushing’s syndrome symptoms only in 1% of cases [7]. This fact 
can be explained by slight, subclinical production of hormones, 
which can be detected in biochemical tests, but insufficient to 
cause clinical symptoms. Immunohistochemical profile found in 
the histopathological examination did not allow to diagnose pri-
mary neuroendocrine cancer, but only cancer with neuroendocrine 
differentiation. From the clinical perspective, increased metabol-
ic disturbances proved very important – they made it difficult to 
prepare the patient and provide care during the perioperative pe-
riod, which was also indicated in other papers [8, 10]. Hormonal 
and metabolic status of the patient stabilised over a short time af-
ter the radical surgery, which was reported by other authors [10].
Contrary to other reports, we found an atypical, triple-negative 
nature of the tumour. Previously described 6 cases of breast can-
cer producing adrenocorticotropin always had high expression of 
hormonal receptors, especially the estrogen receptor [4, 8]. Expla-
nations given to this phenomenon indicated the participation of 
ACTH in carcinogenesis dependent on steroid hormones. Ectopic 
production of ACTH caused by a triple-negative cancer denies such 
a relationship and indicates the necessity to seek other theories. 
Prognosis in primary breast cancers with ACTH production de-
pends on tumour biology and cancer staging; it is clearly better in 
cases with low, clinically insignificant concentrations of adreno-
corticotropin [9]. High concentration of hormones, advanced stage 
of tumour, high histological grade and triple-negative molecular 
subtype in the described case, were adverse prognostic factors and 
indicated a necessity of aggressive adjuvant treatment. 
In the presented case, the etoposide and cisplatin chemotherapy 
reserved for neuroendocrine tumors is highly controversial. In the 
opinion of the authors, anthracyclines in combination with tax-
anes would be more reasonable, however, due to the change of the 
treatment center it is difficult to undertake appropriate discussion.
conclusIons
Although there are no definitive guidelines for the treatment of 
this type of cancer, it appears that the strategy should not deviate 
from the general rules of breast cancer treatment. Coexistence of 
serious hormonal and metabolic disturbances – like in the pre-
sented case – indicates that it is necessary to use an individualised 
approach in the oncological treatment. 
tes was controlled with insulin therapy and kalemia was stabilised 
at 3.0 mmol/L. Due to symptoms of cardiac insufficiency and di-
agnosed thrombocytopenia (51000/µl with normal bone marrow 
biopsy results) the patient also required preoperative cardiac and 
haematological preparation. During the patient’s stay at the sur-
gery ward, a modified radical mastectomy of the right breast was 
performed using the Madden technique. There were no postop-
erative complications. Within the subsequent 14 days of hospi-
talisation, the patient’s metabolism gradually stabilised, the level 
of ACTH and cortisol in blood serum normalised (cortisol 16.86 
µg/dL [8 am], ACTH 9.8 pg/mL) and the number of platelets be-
came stable. The patient was then discharged from the hospital. 
Histopathological examination of a surgical specimen allowed to 
diagnose invasive breast cancer with neuroendocrine differentia-
tion G3 at stage pT3N1a. In 3 out of 23 excised lymph nodes, mac-
rometastases were found, the largest with a diameter of 19 mm, 
extending from the lymph node capsule and infiltrating the sur-
rounding fat tissue. Isolated cancer cells were found in further two 
lymph nodes. Immunohistochemically, the cancer cells indicated 
the presence of NSE (neuron-specific enolase) in less than 50% of 
cells. However, expression of chromogranin, synaptophysin, CD56, 
TTF1, CK5/6, p63 and somatostatin receptors (carried out using 
rabbit antibodies SSTR 1-5 (Gramsch Laboratories) at a dilution 
of 1/500)  was not found. The triple-negative nature of the cancer 
(ER-0, PGR-0, HER2-negative) was confirmed.  At the next stage, 
the patient received adjuvant treatment in another clinic, closer 
to her place of residence. Probably based on the neuroendocrine 
character of the tumor, she was qualified for adjuvant EP chemo-
therapy (VI cycles of etoposide and cisplatin). The patient was 
treated also with radiotherapy. Four months after the last cycle, 
metastases to the liver and mediastinal lymph nodes were found 
in CT. In scintigraphy with 99m-Tc-labelled somatostatin analogs, 
metastases showed no expression of the receptor. The patient un-
derwent second-line chemotherapy, but control CT revealed pro-
gression of liver metastases and bone dissemination. Finally, the 
patient died 20 months after surgery and two months after the last 
cycle of chemotherapy.
dIscussIon
The term paraneoplastic syndrome is used to describe a group 
of symptoms occurring in the course of cancer and resulting not 
Fig. 1.  SPECT/CT scan after administration of 99mTc-somatostatin analogue showing 
the presence of somatostatin receptors in the right breast tumor.
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